These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19182362)

  • 21. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.
    Hutchison AJ; Gill M; Copley JB; Poole L; Wilson RJ
    BMC Nephrol; 2013 Feb; 14():40. PubMed ID: 23418668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Radiographic characteristics of lanthanum carbonate absorption].
    Vrigneaud L; Lefèbvre D; Daem AO; Lemaitre V
    Nephrol Ther; 2008 Apr; 4(2):111-3. PubMed ID: 18243834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
    Vemuri N; Michelis MF; Matalon A
    BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
    Koiwa F; Sato Y
    Clin Calcium; 2009 Feb; 19(2):198-204. PubMed ID: 19182359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Management of hyperphosphatemia ; phosphate-binder].
    Yokoyama K
    Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis.
    Vegter S; Tolley K; Keith MS; Postma MJ
    Value Health; 2011; 14(6):852-8. PubMed ID: 21914505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
    Ketteler M
    Int J Artif Organs; 2009 Feb; 32(2):95-100. PubMed ID: 19363781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.
    Ando R; Kimura H; Sato H; Iwamoto S; Yoshizaki Y; Chida Y; Ishida Y; Takayama M; Yamada K; Tachibana K; Ohtsuka M; Kikuchi K; Inoue A
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():2-8. PubMed ID: 23586506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sevelamer carbonate.
    Barna MM; Kapoian T; O'Mara NB
    Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lanthanum carbonate.
    Joy MS; Kshirsagar A; Candiani C; Brooks T; Hudson JQ
    Ann Pharmacother; 2006 Feb; 40(2):234-40. PubMed ID: 16449551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials.
    Wang F; Lu X; Zhang J; Xiong R; Li H; Wang S
    Kidney Blood Press Res; 2018; 43(2):536-544. PubMed ID: 29627829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.
    Xu J; Zhang YX; Yu XQ; Liu ZH; Wang LN; Chen JH; Fan YP; Ni ZH; Wang M; Yuan FH; Ding GH; Chen XM; Zhang AP; Mei CL
    BMC Nephrol; 2013 Feb; 14():29. PubMed ID: 23379590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lanthanum carbonate treatment of patients with hyperphosphatemia undergoing CAPD.
    Kawanishi H; Ishida M; Ishizaki M; Takuma Y; Tamura H; Kobayashi S; Tamura T; Ohashi H; Hiramatsu M; Minakuchi J; Hirakata H; Shigematsu T;
    Perit Dial Int; 2008; 28(6):673-5. PubMed ID: 18981401
    [No Abstract]   [Full Text] [Related]  

  • 35. [Studies of the Various Chronic Kidney Failure Rat Models and Hemodialysis Mini-pig Model for the Evaluation of Anti-hyperphosphatemia Drugs].
    Okabe T; Katoh M; Kano M; Okazaki R; Tanaka Y; Toyoda H; Ueno M
    Yakugaku Zasshi; 2019; 139(11):1435-1448. PubMed ID: 31685740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
    Guo H; Zhang X; Tang S; Zhang S
    Ren Fail; 2013; 35(10):1455-64. PubMed ID: 23992043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lanthanum carbonate.
    Freemont AJ
    Drugs Today (Barc); 2006 Dec; 42(12):759-70. PubMed ID: 17285149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
    Shigematsu T; Tokumoto A; Nakaoka A; Arisaka H
    Ther Apher Dial; 2011 Apr; 15(2):176-84. PubMed ID: 21426511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I; Hutchison AJ
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB
    Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.